Expand RARE Menu
RARE MENU

RARE Latest Press Releases

-- October 7, 2026 --

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million Globe Newswire 8:30 AM

-- October 2, 2026 --

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) Globe Newswire 2:00 AM

-- September 24, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 5:35 PM

-- September 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 8:17 PM

-- September 17, 2026 --

Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) Globe Newswire 3:48 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:02 AM

-- September 8, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 5:32 PM

-- September 2, 2026 --

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Globe Newswire 4:01 PM

-- September 1, 2026 --

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease Globe Newswire 4:05 PM

-- August 25, 2026 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- August 19, 2026 --

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) Globe Newswire 5:21 PM

-- August 4, 2026 --

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update Globe Newswire 4:05 PM

-- July 28, 2026 --

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update Globe Newswire 4:05 PM

-- July 24, 2026 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- July 15, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE) Globe Newswire 11:33 AM

-- July 8, 2026 --

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact Globe Newswire 9:08 AM

-- June 23, 2026 --

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors Globe Newswire 8:00 AM

-- June 19, 2026 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- June 4, 2026 --

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm PRNewswire 4:36 PM

-- June 3, 2026 --

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 4:30 PM

-- June 2, 2026 --

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm Globe Newswire 12:09 PM

-- May 22, 2026 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes